Piper Jaffray analyst Joseph Catanzaro raised his price target for Iovance Biotherapeutics to $30 from $20 after spending two days hosting investor meetings with management. The analyst came away optimistic on a near term favorable regulatory update in cervical cancer. The FDA will, at minimum, accept some subset of the current cohort, which would allow enrollment to complete by the end of 2019 and a filing to occur ahead of the planned late-2020 melanoma submission, Catanzaro tells investors in a research note. As a result, he pushed U.S. cervical revenue into 2021. The analyst keeps an Overweight rating on shares of Iovance.